Kevin T. Hogan

A Multipeptide Vaccine is Safe and Elicits T-cell Responses in Participants With Advanced Stage Ovarian Cancer

Kimberly A. Chianese‐Bullock, William P. Irvin, Gina R. Petroni et al. · Journal of Immunotherapy · 2008 · 110 citations

Treatment of ovarian cancer cell lines with 5-aza-2′-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules

Sara J. Adair, Kevin T. Hogan · Cancer Immunology Immunotherapy · 2008 · 101 citations · Full text

Oncology, Medicine, Tumor Immunity +10

The peptide recognized by HLA-A68.2-restricted, squamous cell carcinoma of the lung-specific cytotoxic T lymphocytes is derived from a mutated elongation factor 2 gene.

Kevin T. Hogan, Dominic Eisinger, S B Cupp et al. · PubMed · 1998 · 92 citations

Immunocytochemical Technique, Squamous Cell Carcinoma, Immunology +19

A Fractal Clonotype Distribution in the CD8+ Memory T Cell Repertoire Could Optimize Potential for Immune Responses

Yuri N. Naumov, Elena N. Naumova, Kevin T. Hogan et al. · The Journal of Immunology · 2003 · 86 citations

Mutations in the alpha 2 helix of HLA-A2 affect presentation but do not inhibit binding of influenza virus matrix peptide.

Kevin T. Hogan, Naoki Shimojo, Scott F. Walk et al. · The Journal of Experimental Medicine · 1988 · 82 citations · Full text

Class Ii, Viral Replication, Mhc Class +17